Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative short-course radiotherapy and CAPOX for rectal cancer
IRCT20190119042415N1Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in rectal cancer, sponsored by Shiraz University of Medical Sciences. Primary endpoints: Pathologic complete response and Side effects. Started Mar 2019; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on IRCT20190119042415N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190119042415N1.